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Abstract
Background: Peutz-Jeghers syndrome (PJS) is an unusual autosomal dominant disorder
characterized by mucocutaneous pigmentation and multiple gastrointestinal hamartomatous
polyps. Patients with PJS are at an increased risk of developing multi-organ cancer, most frequently
those involving the gastrointestinal tract. Germline mutation of the STK11 gene, which encodes a
serine-threonine kinase, is responsible for PJS.
Methods: Using DNA samples obtained from the patient and his family members, we sequenced
nine exons and flanking intron regions of the STK11 gene using polymerase chain reaction (PCR)
and direct sequencing.
Results: Sequencing of the STK11 gene in the proband of the family revealed a novel 1-base pair
deletion of guanine (G) in exon 6 (c.826delG; Gly276AlafsX11). This mutation resulted in a
premature termination at codon 286, predicting a partial loss of the kinase domain and complete
loss of the C-terminal domain. We did not observe this mutation in both parents of the PJS patient.
Therefore, it is considered a novel de novo mutation.
Conclusion: The results presented herein enlarge the spectrum of mutations of the STK11 gene
by identifying a novel de novo mutation in a PJS patient and further support the hypothesis that
STK11 mutations are disease-causing mutations for PJS with or without a positive family history.
Background
Peutz-Jeghers syndrome (PJS; OMIM 175200) is a rare,
autosomal dominant disorder characterized by melano-
cytic macules of the lips, buccal mucosa, and digits, along
with multiple gastrointestinal hamartomatous polyps, fre-
quently in the small intestine [1,2]. Patients with PJS are
at an increased risk of developing gastrointestinal cancer
and extraintestinal neoplasms involving organs such as
the ovaries, testes, breasts, pancreas, lungs, or uterine cer-
vix [3].
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as LKB1; OMIM 602216) at chromosome 19p13.3 have
been identified as a cause of PJS [4,5]. The human STK11
gene encodes a 433 amino acid serine-threonine kinase.
STK11 is known to be located both in the nucleus and the
cytoplasm of all human tissues [6], and orthologs include
mouse LKb1 [7], XEEK1 (Xenopus egg and embryo kinase
1) [8], Caenorhabditis elegans partitioning defective gene 4
(par-4) [9], and drosophila Lkb1 [10].
Loss of the normal allele has been observed in polyps
from patients with PJS, and loss of heterozygosity (LOH)
has been noted to occur in some tumor tissues, suggesting
that STK11 is a tumor suppressor gene [11]. STK11 has
been shown to cause apoptosis in intestinal epithelial
cells, and is physically associated with p53, regulating spe-
cific p53-dependent apoptosis pathways [12]. STK11 is
also known to have effects on G1 cell cycle arrest [13],
TGF-β signaling [14], polarity [15], and phosphorylating
and activating the AMP-activated protein kinase (AMPK)
[16].
Screening for point mutations and large deletions by
direct sequencing or by multiplex ligation-dependent
probe amplification (MLPA) increased the mutation
detection rate in the STK11 gene up to 94% [17]. To date,
more than 200 different mutations in the STK11 gene
have been reported at the Human Gene Mutation Data-
base (HGMD) website http://www.hgmd.cf.ac.uk/ac/
all.php and most are small insertions/deletions or mis-
sense/nonsense mutations.
We report on a Korean PJS patient with a novel STK11
mutation. During molecular genetic testing for STK11
mutation, we detected a novel small deletion in exon 6,
causing a premature stop codon. This mutation was
absent in both parents of the patient and was thus a de
novo mutation.
Methods
Subjects
The proband was a 13-year-old Korean male. He was diag-
nosed clinically with PJS at six years of age based on the
presence of characteristic mucocutaneous pigmentation
of the lips and buccal mucosa, and gastrointestinal
hamartomatous polyps after polypectomy (Figure 1).
After obtaining informed consent, blood samples were
collected from four family members including the patient.
Brother and parents of the patient did not consent to
endoscopic examinations for evaluation of polyps. Rela-
tives of the patient had no known medical conditions,
including mucocutaneous pigmentation or malignancies,
and no further study was assessed (Figure 2).
Mutation studies
Four family members including the patient were included
in this study after obtaining informed consent. The
genomic DNA was isolated from peripheral blood leuko-
cytes using the Wizard Genomic DNA Purification Kit
according to the manufacturer's instructions (Promega,
Madison, WI, USA). The polyp tissue was not collected for
DNA analysis. The STK11 gene was amplified via PCR [by
using the appropriate primers as designed by the authors
(available upon request)] and a thermal cycler (Model
9700; Applied Biosystems, Foster City, CA, USA). Direct
sequencing of all nine coding exons along with the flank-
ing intron regions of the STK11 gene was performed with
the Big Dye Terminator Cycle Sequencing Ready Reaction
Kit (Applied Biosystems) in conjunction with an ABI
Prism 3100 automated genetic analyzer (Applied Biosys-
tems).
Results
Direct sequencing analysis of the proband demonstrated
a heterozygous 1-bp deletion of guanine (G) (c.826delG;
Gly276AlafsX11) in exon 6 of the STK11 gene, which
resulted in a frameshift leading to premature termination
of the 433 amino acid protein at the 286th codon, disrup-
tion of the kinase domain, and complete loss of carboxy-
terminal non-catalytic region. This mutation was absent
in his family members and 100 control chromosomes
(Figure 3).
Pathologic findings of the Peutz-Jeghers polypFigure 1
Pathologic findings of the Peutz-Jeghers polyp. The 
colonic polyp shows hyperplastic mucosal epithelium and 
arborizing pattern of smooth muscle, consistent with a 
hamartomatous polyp (Hematoxylin-eosin stain, 200×).Page 2 of 5
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Germline mutations in the STK11 gene on chromosome
19p13.3 have been shown to be the cause of PJS [4,5].
Recent study suggests that the STK11 mutation detection
rate was above 90% [17]. However, some families with
PJS have shown linkage to chromosomal region 19q13.4
[18] and 6 [19]. Human STK11 consists of nine coding
exons with a 433 amino acid coding sequence, and one
non-coding exon 10 that spans 23 kb [6,7]. The STK11
protein is mainly comprised of three major domains: the
N-terminal non-catalytic domain containing the nuclear
localization signal, the catalytic kinase domain important
for ATP binding, and the carboxyterminal non-catalytic
regulatory domain containing prenylation motif (CAAX-
box). Codons 49–309 encode the catalytic kinase domain.
The C-terminal non-catalytic region of the STK11 protein
is encoded by exon 8 and 9 and encompasses amino acids
309–433.
The patient recruited in this study fulfilled the well-estab-
lished clinical diagnostic criteria for PJS [20]. The criteria
include histopathologically proven hamartomas together
with classical mucocutaneous hyperpigmentation and
small-bowel polyposis. Therefore, the possibility that this
patient is affected with hamartomatous polyposis syn-
dromes other than PJS is highly unlikely. Such syndromes
include juvenile polyposis syndrome, PTEN hamartoma
tumor syndrome, and Carney complex. In our study, we
sequenced the STK11 gene in this patient with PJS. We
identified a novel heterozygous 1-bp deletion (c.826delG;
Gly276AlafsX11) in exon 6 of the STK11 gene, which
resulted in a frameshift leading to premature termination
of the 433 amino acid protein at the 286th codon. This
mutation was not detected in the STK11 sequencing anal-
ysis of his family members, indicating that
Gly276AlafsX11 is a novel de novo mutation.
The Gly276AlafsX11 mutation is located in the catalytic
kinase domain of STK11 protein, so we hypothesize that
this mutation may lead to partial loss of the kinase
domain and complete loss of the C-terminal domain. This
mutation is novel, but a similar effect of the mutation in
the STK11 protein was reported recently [21]. Loss of
STK11 protein kinase activity associated with loss of
growth suppression function was reported in some muta-
tions in STK11 associated with PJS [4,22]. Thus, develop-
ment of the PJS phenotypes is believed to be due to the
elimination of the kinase activity of STK11 [23]. The C-ter-
minal domain of STK11 is important for the control of
both the AMPK pathway and cell polarity [15]. Mutations
Pedigree of the family with PJSFigu  2
Pedigree of the family with PJS. Circle, female; square, male; black symbol, affected. Asterisk (*) indicates the family member 
who was available for genetic analysis.Page 3 of 5
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observed in this case, lead to loss of cell polarity, resulting
in the development of malignancies. Taken together,
these data suggest that the STK11 mutation in exon 6 may
contribute to polyp formation and tumorgenesis through
various mechanisms such as loss of growth arrest, apopto-
sis, and loss of cell polarity. Further studies will be needed
to address these questions.
Although an increased cancer risk in patients with PJS is
well established [3,24], data on genotype-phenotype cor-
relation is lacking. Schumacher et al. studied 146 PJS
patients and determined that inframe deletions, splice site
mutations, and missense mutations in the catalytic kinase
domain were rarely associated with cancer. However, it
was felt that missense mutations in the C-terminal
domain were more frequently associated with malignan-
cies [22]. Recently, however, Hearle et al. studied 419 PJS
patients and determined that the type or site of the STK11
mutation did not significantly influence cancer risk [25].
Restricted by the few published papers on this topic, the
genotype-phenotype correlation remains to be further
investigated.
Conclusion
We enlarged the spectrum of mutations of the STK11 gene
by identifying a novel mutation in a Korean patient with
PJS. Because of the increased risk of PJS in patients with
multi-organ cancers, molecular diagnosis will be an
important factor in genetic counseling, clinical manage-
ment of patients, and tumor screening.
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Identification of the STK11 gene mutationFigure 3
Identification of the STK11 gene mutation. Direct sequencing of the proband demonstrated a 1-bp deletion (c.826delG) 
in exon 6 of the STK11 gene, resulting in a frameshift deletion mutation (p.Gly276AlafsX11). The proband's family members did 
not have the mutation. The localization of the deletion is indicated by the arrow.Page 4 of 5
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